Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells

详细信息    查看全文

• 作者：Svetlana Skolekova ; Miroslava Matuskova ; Martin Bohac…
• 关键词：Adipose tissue ; derived mesenchymal stromal cells ; Apoptosis ; Cell signaling ; Human breast cancer ; Chemoresistance
• 刊名：Cell Communication and Signaling
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：14
• 期：1
• 全文大小：1,689 KB
• 参考文献：1.Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665–74. doi:10.​1038/​nrc2714 .PubMed CrossRef
  2.Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359–68. doi:10.​1038/​nm.​2890 .PubMed PubMedCentral CrossRef
  3.Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–4. doi:10.​1038/​nature11183 .PubMed PubMedCentral CrossRef
  4.Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505–9. doi:10.​1038/​nature11249 .PubMed PubMedCentral CrossRef
  5.Castells M, Milhas D, Gandy C, Thibault B, Rafii A, Delord JP, et al. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis. 2013;4:e887. doi:10.​1038/​cddis.​2013.​384 .PubMed PubMedCentral CrossRef
  6.Tiago M, de Oliveira EM, Brohem CA, Pennacchi PC, Paes RD, Haga RB et al. Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin. Tissue Eng Part A. 2014. doi:10.​1089/​ten.​TEA.​2013.​0473 .
  7.Kucerova L, Skolekova S. Tumor microenvironment and the role of mesenchymal stromal cells. Neoplasma. 2013;60(1):1–10. doi:10.​4149/​neo_​2013_​001 .PubMed CrossRef
  8.Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10(6):709–16. doi:10.​1016/​j.​stem.​2012.​05.​015 .PubMed CrossRef
  9.Hass R, Otte A. Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Commun Signal. 2012;10(1):26. doi:10.​1186/​1478-811X-10-26 .PubMed PubMedCentral CrossRef
  10.Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011;20(3):370–83. doi:10.​1016/​j.​ccr.​2011.​08.​010 .PubMed CrossRef
  11.Kucerova L, Skolekova S, Matuskova M, Bohac M, Kozovska Z. Altered features and increased chemosensitivity of human breast cancer cells mediated by adipose tissue-derived mesenchymal stromal cells. BMC Cancer. 2013;13:535. doi:10.​1186/​1471-2407-13-535 .PubMed PubMedCentral CrossRef
  12.Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Res. 2011;71(15):5062–6. doi:10.​1158/​0008-5472.​CAN-11-0277 .PubMed PubMedCentral CrossRef
  13.Kucerova L, Kovacovicova M, Polak S, Bohac M, Fedeles J, Palencar D, et al. Interaction of human adipose tissue-derived mesenchymal stromal cells with breast cancer cells. Neoplasma. 2011;58(5):361–70.PubMed CrossRef
  14.Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129. doi:10.​1186/​1476-4598-9-129 .PubMed PubMedCentral CrossRef
  15.Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011;71(2):614–24. doi:10.​1158/​0008-5472.​CAN-10-0538 .PubMed PubMedCentral CrossRef
  16.Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63. doi:10.​1038/​nature06188 .PubMed CrossRef
  17.Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670–3. doi:10.​1126/​science.​1171837 .PubMed PubMedCentral CrossRef
  18.Januchowski R, Wojtowicz K, Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013;67(7):669–80. doi:10.​1016/​j.​biopha.​2013.​04.​005 .PubMed CrossRef
  19.Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520(7547):368–72. doi:10.​1038/​nature14336 .PubMed PubMedCentral CrossRef
  20.Kucerova L, Poturnajova M, Tyciakova S, Matuskova M. Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase. Stem Cell Res. 2012;8(2):247–58.PubMed CrossRef
  21.Liang W, Xia H, Li J, Zhao RC. Human adipose tissue derived mesenchymal stem cells are resistant to several chemotherapeutic agents. Cytotechnology. 2011;63(5):523–30. doi:10.​1007/​s10616-011-9374-5 .PubMed PubMedCentral CrossRef
  22.Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67(13):6304–13. doi:10.​1158/​0008-5472.​CAN-06-4024 .PubMed CrossRef
  23.Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 2012;31(26):3148–63. doi:10.​1038/​onc.​2011.​485 .PubMed CrossRef
  24.Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010;18(6):884–901. doi:10.​1016/​j.​devcel.​2010.​05.​012 .PubMed PubMedCentral CrossRef
  25.Spano D, Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis. 2012;29(4):381–95. doi:10.​1007/​s10585-012-9457-5 .PubMed CrossRef
  26.Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med. 2012;18(9):1332–4. doi:10.​1038/​nm.​2938 .PubMed CrossRef
  27.Dittmer J, Leyh B. The impact of tumor stroma on drug response in breast cancer. Semin Cancer Biol. 2015;31:3–15. doi:10.​1016/​j.​semcancer.​2014.​05.​006 .PubMed CrossRef
  28.Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22. doi:10.​1016/​j.​ccr.​2012.​02.​022 .PubMed CrossRef
  29.Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE. The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer. 2012;106(12):1901–6. doi:10.​1038/​bjc.​2012.​201 .PubMed PubMedCentral CrossRef
  30.Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8. doi:10.​1073/​pnas.​0530291100 .PubMed PubMedCentral CrossRef
  31.Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014;2(1):78–91. doi:10.​1016/​j.​stemcr.​2013.​11.​009 .CrossRef
  32.Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67. doi:10.​1016/​j.​stem.​2007.​08.​014 .PubMed PubMedCentral CrossRef
  33.Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007;21(11):1396–408. doi:10.​1101/​gad.​1553707 .PubMed PubMedCentral CrossRef
  34.Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediat Inflamm. 2014;2014:292376. doi:10.​1155/​2014/​292376 .CrossRef
  35.Yi EH, Lee CS, Lee JK, Lee YJ, Shin MK, Cho CH, et al. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 2013;11(1):31–42. doi:10.​1158/​1541-7786.​MCR-12-0217 .PubMed CrossRef
  36.Xu BE, Stippec S, Lenertz L, Lee BH, Zhang W, Lee YK, et al. WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J Biol Chem. 2004;279(9):7826–31. doi:10.​1074/​jbc.​M313465200 .PubMed CrossRef
  37.Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747–58. doi:10.​1038/​nrm2509 .PubMed CrossRef
  38.Laberge RM, Awad P, Campisi J, Desprez PY. Epithelial-mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron. 2012;5(1):39–44. doi:10.​1007/​s12307-011-0069-4 .PubMed PubMedCentral CrossRef
  39.Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267(2):271–85. doi:10.​1016/​j.​canlet.​2008.​03.​018 .PubMed CrossRef
  40.Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood. 2011;118(20):5540–9. doi:10.​1182/​blood-2011-04-351742 .PubMed PubMedCentral CrossRef
  41.Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210. doi:10.​1186/​1471-2407-11-210 .PubMed PubMedCentral CrossRef
  42.Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17(5):325–37. doi:10.​1016/​j.​cytogfr.​2006.​07.​002 .PubMed CrossRef
  43.Chen DR, Lu DY, Lin HY, Yeh WL. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. BioMed Res Int. 2014;2014:532161. doi:10.​1155/​2014/​532161 .PubMed PubMedCentral
  44.Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9 Suppl 1:2–10.PubMed CrossRef
  45.Nadler Y, Gonzalez AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol. 2010;21(3):466–73. doi:10.​1093/​annonc/​mdp346 .PubMed PubMedCentral CrossRef
  46.McCorkle JR, Leonard MK, Kraner SD, Blalock EM, Ma D, Zimmer SG, et al. The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma. Cancer Genomics Proteomics. 2014;11(4):175–94.PubMed PubMedCentral
  47.Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015;212(7):1043–59. doi:10.​1084/​jem.​20141836 .PubMed PubMedCentral CrossRef
  48.Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Ruegg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010;30(6):529–45.PubMed CrossRef
  49.Andre F, Berrada N, Desmedt C. Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol. 2010;22(6):547–51. doi:10.​1097/​CCO.​0b013e32833fb384​ .PubMed CrossRef
  
• 作者单位：Svetlana Skolekova (1)
  Miroslava Matuskova (1)
  Martin Bohac (2)
  Lenka Toro (1)
  Lucia Demkova (1)
  Jan Gursky (3)
  Lucia Kucerova (1)
  
  1. Laboratory of Molecular Oncology, Cancer Research Institute, Slovak Academy of Sciences, Vlarska 7, 833 91, Bratislava, Slovakia
  2. Department of Plastic, Aesthetic and Reconstructive Surgery, University Hospital, Bratislava, Slovakia
  3. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, Olomouc, Czech Republic
  
• 刊物主题：Cell Biology; Protein-Ligand Interactions; Receptors; Cytokines and Growth Factors;
• 出版者：BioMed Central
• ISSN：1478-811X

文摘

Background Cells of the tumor microenvironment are recognized as important determinants of the tumor biology. The adjacent non-malignant cells can regulate drug responses of the cancer cells by secreted paracrine factors and direct interactions with tumor cells.